Why myeloma records are read as a set, not a stack
Multiple myeloma is assessed through combined criteria, not a single number. The International Myeloma Working Group updated its diagnostic criteria in 2014 to include specific biomarkers alongside the classic findings of clonal plasma cells, monoclonal protein and organ damage. That means a specialist reassessing your case needs to see how the pieces fit: the marrow result, the protein studies, the blood counts, kidney function, calcium and bone findings, and the cytogenetic or FISH results that describe the clone.
A folder of unrelated reports is hard to interpret because timing matters. A marrow biopsy from before treatment describes the disease at diagnosis. A later one may describe residual disease or a change in behaviour. A serum free light chain result means little without the date, the reference range used by that laboratory and the corresponding serum and urine protein electrophoresis. When you send records for a care decision in China, the receiving haematology team will be asking what changed, when, and in response to which treatment.
This is also why a remote records review has limits. A specialist can comment on the documented pattern and identify what is missing, but cannot confirm current disease status without current results. The treating hospital decides suitability for any plan, and a review does not establish eligibility for a clinical trial, transplant or any specific therapy.
The diagnostic core: marrow, protein studies and genetics
The records most likely to change a decision are the ones that establish the diagnosis and the biology of the clone. Ask the original hospital for the full pathology report of the bone marrow biopsy, not only the conclusion line. The report should describe the percentage of clonal plasma cells and any immunohistochemistry or flow cytometry used to characterise them. If a second marrow was done later, include it with its date and the reason it was performed.
Protein studies form the second core. Serum protein electrophoresis, immunofixation, urine protein electrophoresis and serum free light chain assays together describe the monoclonal protein and, in light chain disease, the involved and uninvolved light chains. The International Myeloma Working Group response criteria depend on these measurements, so a care decision about whether prior treatment worked needs the actual values over time, not a clinician's summary that the patient 'responded well'.
Cytogenetics and FISH matter because they inform risk stratification. The IMWG and the National Comprehensive Cancer Network describe high-risk features that influence prognosis and sometimes treatment choice. Ask for the full FISH panel report, including which probes were used and the percentage of cells with each abnormality. A report that says only 'abnormal' is much less useful than one listing del(17p), t(4;14), t(14;16) or gain(1q) with the laboratory's own interpretation.
Staging records also belong here. The International Staging System uses serum beta-2 microglobulin and albumin, and the revised ISS adds selected cytogenetic and lactate dehydrogenase information. Include the laboratory values and dates that were used, so the receiving team can see how staging was derived rather than accepting a label.
- Full marrow pathology reports with dates and plasma cell percentage
- Serum and urine electrophoresis plus immunofixation results
- Serum free light chain values with the laboratory reference range
- FISH and cytogenetic reports listing the specific abnormalities tested
- The laboratory values behind any stated ISS or R-ISS stage
Treatment history and response: what the next team needs to see
A myeloma care decision is usually about what to do next, and that depends on what has already been given and how the disease responded. Build a dated table of every regimen: the drug names, the start and stop dates, the number of cycles completed, and any dose reductions or interruptions with the reason. Include steroids, immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies and any chemotherapy, because the sequence and combinations affect what options remain.
Response documentation should follow the same logic. The IMWG uniform response criteria define categories such as partial response, very good partial response, complete response and progressive disease using specific changes in monoclonal protein, free light chains and marrow findings. If your records state a response category, include the underlying measurements and the date they were taken. If no formal assessment was recorded, say so rather than reconstructing one from memory.
Also document adverse effects that changed treatment. Peripheral neuropathy, infection, thrombosis, kidney injury or cardiac events can influence which agents a treating team considers. A short factual note with dates is more useful than a general statement that a drug 'did not suit'. Include any supportive medicines that are ongoing, such as antivirals, anticoagulants or bone-protective treatment, because the receiving team needs the current medication list to assess interactions.
If you have had a stem cell transplant, include the transplant summary, the stem cell source, the conditioning approach and the engraftment record. This is not a claim that transplant or any therapy will be available in China; it is information the treating team needs to understand your history.
Current disease status: blood, urine, imaging and bone health
Past records explain the journey; current results describe the decision in front of you. Ask your treating centre for the most recent complete blood count with differential, kidney function, calcium, albumin, beta-2 microglobulin and lactate dehydrogenase, each with its date and reference range. These are the values that show whether the disease is stable, responding or progressing, and whether organs such as the kidneys are affected.
Imaging records should include the actual reports and, where possible, the images or a way for the receiving hospital to access them. The IMWG imaging recommendations describe whole-body low-dose CT, MRI and PET/CT in different situations, and the choice depends on the clinical question. Do not assume one scan substitutes for another. If you have had a skeletal survey, whole-body MRI or PET/CT, send the report and note the date and the hospital where it was done.
Bone health deserves its own line in the file. Include any history of fractures, spinal imaging, radiotherapy to bone, or treatment with bisphosphonates or denosumab, with dates. The treating team will want to know about dental history and kidney function before considering bone-protective drugs, and those decisions belong to the clinicians assessing you.
Finally, include a short current symptom and function summary written by you: pain, fatigue, infections, neuropathy, mobility and any recent hospital admissions. This helps the receiving team understand the person behind the results, and it is information only you can supply.
What a records-based opinion can and cannot settle
A specialist reviewing records from a distance can assess the documented diagnosis, prior response and risk features, identify gaps, and suggest questions the local team should address. That is genuinely useful before deciding whether to travel. It cannot confirm current disease status without current tests, cannot guarantee hospital acceptance, and does not establish access to any particular medicine, trial or transplant programme.
Be cautious about any service that implies a remote review settles treatment. Myeloma care depends on repeated laboratory assessment and clinical examination, and the treating haematology team in China will make its own evaluation. If you are considering care in China, ask the hospital directly which records it requires, whether it needs tests repeated locally, and how it handles records in another language. Translation requirements and document rules vary by hospital, so confirm them rather than assuming a standard.
If your disease is progressing quickly, has caused new kidney injury, severe pain or spinal symptoms, or you are unwell now, seek urgent local medical assessment rather than waiting on an overseas records review. Travel planning should follow clinical stabilisation, not precede it.
Preparing the file and the first enquiry
Organise records chronologically with a one-page index: diagnosis date, key test dates, treatment lines with responses, current medications and the specific question you want answered. Send the index and the most decision-relevant reports first. A brief summary at first contact is enough; detailed records can follow once the team confirms what it needs. Do not send passport numbers, payment details or a complete archive through an initial form.
For a China enquiry, the free initial case review checks the available diagnosis, records and your main question, identifies missing information and suggests a relevant next step. It is not a diagnosis or a promise of acceptance. A proxy consultation, where a doctor takes records to a hospital specialist while you remain at home, is optional and not a prerequisite for an appointment. Hospital consultation fees and treatment costs are separate from coordination fees, and the hospital provides its own written quote for care.
The practical next step is to gather the diagnostic marrow and FISH reports, the protein and light chain results over time, the treatment and response table, and the most recent blood, urine and imaging results. Then send a short summary with your main question so the team can tell you what is missing before any care decision is discussed.
Sources & scope of this guide
References and official service information relevant to this guide.
- radiotherapy
- Related treatment reference
- Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®) - NCI
This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.
